Comparing Profusa (PFSA) & Its Rivals

Profusa (NASDAQ:PFSA) is one of 27 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its rivals? We will compare Profusa to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, risk, profitability, dividends and valuation.

Earnings and Valuation

This table compares Profusa and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profusa	N/A	-$8.71 million	-0.01
Profusa Competitors	$61.19 million	-$27.52 million	1.49

Profusa’s rivals have higher revenue, but lower earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Profusa has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Profusa’s rivals have a beta of 1.80, suggesting that their average stock price is 80% more volatile than the S&P 500.

Institutional & Insider Ownership

9.8% of Profusa shares are held by institutional investors. Comparatively, 19.3% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 11.4% of Profusa shares are held by company insiders. Comparatively, 19.9% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Profusa and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Profusa Competitors	-569.68%	-123.14%	-53.62%

Analyst Ratings

This is a summary of recent ratings and target prices for Profusa and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Profusa Competitors	80	82	163	7	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 54.99%. Given Profusa’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Profusa has less favorable growth aspects than its rivals.

Summary

Profusa rivals beat Profusa on 10 of the 13 factors compared.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.